Rituximab and chemotherapy in HIV-related non-Hodgkin lymphomas: review of the literature
| . | R-CDE141 . | R-CHOP143 . | R-CHOP144 . | R-CHOP145 . | R-EPOCH146 . |
|---|---|---|---|---|---|
| No. of patients | 74 | 61 | 95 | 60 | 51 |
| Stage III-IV (%) | 70 | 69 | 80 | 63 | 70 |
| Histology, % | |||||
| Diffuse large cell or variants | 72 | 72 | 81 | 100 | 74 |
| Burkitt or Burkitt-like | 28 | 26 | 8 | 0 | 26 |
| PBL of the oral cavity type | 0 | 2 | 1 | 0 | 0 |
| IPI at least 2, % | 57 | 48 | 58 | 64 | 69 |
| Median CD4/dL | 161 | 172 | 128 | 152 | 181 |
| Complete remission rate, % | 70 | 77 | 57 | 66 | 69 |
| Febrile neutropenia, % | 31 | 25 | 32 | NA | 16 |
| Deaths from infections, % | 7 | 2 | 11 | 5 | 10 |
| . | R-CDE141 . | R-CHOP143 . | R-CHOP144 . | R-CHOP145 . | R-EPOCH146 . |
|---|---|---|---|---|---|
| No. of patients | 74 | 61 | 95 | 60 | 51 |
| Stage III-IV (%) | 70 | 69 | 80 | 63 | 70 |
| Histology, % | |||||
| Diffuse large cell or variants | 72 | 72 | 81 | 100 | 74 |
| Burkitt or Burkitt-like | 28 | 26 | 8 | 0 | 26 |
| PBL of the oral cavity type | 0 | 2 | 1 | 0 | 0 |
| IPI at least 2, % | 57 | 48 | 58 | 64 | 69 |
| Median CD4/dL | 161 | 172 | 128 | 152 | 181 |
| Complete remission rate, % | 70 | 77 | 57 | 66 | 69 |
| Febrile neutropenia, % | 31 | 25 | 32 | NA | 16 |
| Deaths from infections, % | 7 | 2 | 11 | 5 | 10 |
PBL indicates plasmablastic lymphoma; R-CDE, rituximab–cyclophosphamide, doxorubicin, etoposide; R-CHOP, rituximab–cyclophosphamide, vincristine, doxorubicin, prednisone; and R-EPOCH, rituximab–cyclophosphamide, doxorubicin, etoposide, vincristine, prednisone.